

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND CLARAFICATION OF PRESS NEWS

This statement is made at the request of The Stock Exchange of Hong Kong Limited.

The board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) has noted today’s decrease in the price and increase in the trading volume of the shares of the Company and wish to state that the Board is not aware of any reason for such movements.

The Board also refers to certain articles appeared in local newspapers recently regarding the reduction (the “Reduction”) of the highest retail prices of the antibiotics and other medicines with effect from 12 December 2010 as announced by the National Development and Reform Commission of the PRC.

The Board wishes to clarify that the Reduction will have impact on certain finished products of the Group and the average reduction rate of the highest retail prices of such finished products is approximately 13%.

The Board wishes to state that the price reduction of 13% is regarding the highest retail prices of the relevant products and will be absorbed among the Group (as manufacturer), the distributors, the hospitals and the retailers. The Group will re-negotiate the ex-factory prices of the finished products affected by the Reduction with its customers. The Board anticipates that the Reduction will not have material adverse impact on the financial and operations of the Group.

Save for the above, the Board confirms that there are no negotiations or agreements relating to intended acquisitions or realisations which are discloseable under rule 13.23 of the Listing Rules, neither is the Board aware of any matter discloseable under the general obligation imposed by rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

Shareholders of the Company and the potential investors are advised to exercise caution when dealing in the shares of the Company.

Made by the order of the Board, the directors of which individually and jointly accept responsibility for the accuracy of this statement.

By Order of the Board of
**The United Laboratories
International Holdings Limited**
Leung Wing Hon
Executive Director

Hong Kong, 1 December 2010

As at the date of this announcement, the Board comprises Mr. Choy Kam Lok , Ms. Peng Wei, Mr. Leung Wing Hon, Mr. Tsoi Hoi Shan, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yuping as executive directors; Ms. Choy Siu Chit as non-executive director; and Mr. Chong Peng Oon, Mr. Huang Bao Guang and Mr. Song Ming as independent non-executive directors.